PDCD1 and chronic obstructive pulmonary disease: Our lung injury model, which is accompanied by surfactant dysfunction, increased alveolar size, and higher expression of COPD-associated gene signatures in the lung of anti–PD-1 therapy–treated aged mice, suggests that anti–PD-(L)1 therapy exacerbates the prelesioned state of lung damage.